Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Acta cir. bras ; 33(8): 664-672, Aug. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-949374

RESUMO

Abstract Purpose: To investigate the correlation of inhaled nitric oxide (NO) on plasma levels of cardiac troponin I (cTnI) and von Willebrand factor (vWF), glycoprotein (GP) IIb/IIIa, granule membrane protein 140 (GMP-140) in rabbits with acute massive pulmonary embolism (PE). Methods: Thirty apanese white rabbits were divided into 3 groups, thrombus were injected in model group (n = 10), NO were inhalated for 24 h after massive PE in NO group (n = 10), saline were injected in control group (n = 10). The concentrations of vWF, GP IIb/IIIa, GMP-140 and cTnI were tested at 4, 8, 12, 16, 20, and 24 h, Correlation analyses were conducted between cTnI and vWF, GP IIb/IIIa, and GMP-140 by Pearson's correlation. Results: The concentration of cTnI and vWF, GP IIb/IIIa, and GMP-140 was increased in the model group, compared to control group. In the inhaled group, the concentrations of cTnI, vWF, GP IIb/IIIa, and GMP-140 were reduced compared to model group. There was a positive correlation between cTnI and vWF, GP IIb/IIIa, and GMP-140. Conclusion: Inhaled nitric oxide can lead to a decrease in levels of cardiac troponin I, von Willebrand factor, glycoprotein, and granule membrane protein 140, after an established myocardial damage, provoked by acute massive pulmonary embolism.


Assuntos
Animais , Coelhos , Embolia Pulmonar/sangue , Fator de von Willebrand/análise , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/análise , Complexo Glicoproteico GPIIb-IIIa de Plaquetas/efeitos dos fármacos , Selectina-P/sangue , Troponina I/sangue , Óxido Nítrico/administração & dosagem , Embolia Pulmonar/patologia , Embolia Pulmonar/tratamento farmacológico , Valores de Referência , Fatores de Tempo , Administração por Inalação , Fator de von Willebrand/efeitos dos fármacos , Reprodutibilidade dos Testes , Resultado do Tratamento , Selectina-P/efeitos dos fármacos , Troponina I/efeitos dos fármacos , Modelos Animais de Doenças , Microtomografia por Raio-X , Ventrículos do Coração/patologia , Miocárdio/patologia
2.
Acta cir. bras ; 33(7): 577-587, July 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-949362

RESUMO

Abstract Purpose: To investigate changes in the plasma concentrations of cardiac troponin I (CTnI), thromboxane A2 (TXA2), prostaglandin I2 (PGI2) and endothelin-1 (ET-1) in rabbits with massive pulmonary embolism (AMPE) and the impact of nitric oxide inhalation (NOI) on these indices. Methods: A total of 30 Japanese rabbits were used to construct an MPE model and were divided into 3 groups equally (n=10), including an EXP group (undergoing modeling alone), an NOI group (receiving NOI 2 h post-modeling) and a CON group (receiving intravenous physiological saline). Results: In the model group, plasma concentration of CTnI peaked at 16 h following modeling (0.46±0.10 µg/ml) and significantly decreased following NOI. Plasma levels of TXB2, PGI2 and ET-1 peaked at 12, 16 and 8 h following modeling, respectively, and significantly decreased at different time points (0, 2, 4, 8, 12, 16, 20 and 24 h) following NOI. A significant correlation was observed between the peak plasma CTnI concentration and peak TXB2, 6-keto prostaglandin F1α and ET-1 concentrations in the model and NOI groups. Conclusion: Increases in plasma TXA2, PGI2 and ET-1 levels causes myocardial damage in a rabbit model of AMPE; however, NOI effectively down regulates the plasma concentration of these molecules to produce a myocardial-protective effect.


Assuntos
Animais , Masculino , Feminino , Coelhos , Embolia Pulmonar/tratamento farmacológico , Embolia Pulmonar/sangue , Tromboxano A2/sangue , Broncodilatadores/farmacologia , Epoprostenol/sangue , Endotelina-1/sangue , Troponina I/sangue , Óxido Nítrico/farmacologia , Embolia Pulmonar/patologia , Valores de Referência , Fatores de Tempo , Administração por Inalação , Ensaio de Imunoadsorção Enzimática , Distribuição Aleatória , Regulação para Baixo , Doença Aguda , Reprodutibilidade dos Testes , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA